MedTrace Logo

Efficacy and Safety Study of Seroquel SR in the Treatment of Generalized Anxiety Disorder

NCT00322595 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 800

Last updated 2008-12-22

No results posted yet for this study

Summary

The primary purpose of this study is to evaluate the efficacy of (SEROQUEL SR™ ) quetiapine fumarate sustained-release (SR) compared to placebo in the treatment of anxiety symptoms in patients with generalized anxiety disorder (GAD).

PLEASE NOTE: Seroquel SR and Seroquel XR refer to the same formulation. The SR designation was changed to XR after consultation with FDA.

Conditions

  • Generalized Anxiety Disorder

Interventions

DRUG

Quetiapine fumarate

DRUG

Paroxetine

Sponsors & Collaborators

Principal Investigators

  • Seroquel Medical Science Director · AstraZeneca

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-05-31
Completion
2007-05-31

Countries

  • Argentina
  • Bulgaria
  • Canada
  • Czechia
  • Denmark
  • Finland
  • France
  • Germany
  • Mexico
  • Norway
  • Romania
  • Slovakia
  • South Africa
  • Spain
  • Sweden

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00322595 on ClinicalTrials.gov